Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials
Patients with dementia with Lewy bodies (DLB) experience worsening axial symptoms with disease progression, which can negatively affect quality of life. Previous phase 2 and 3 clinical trials conducted in Japan showed that zonisamide improved parkinsonism in patients with DLB. In the present study,...
Main Authors: | Yoshio Tsuboi, Kenji Kochi, Hidenori Maruyama, Yuji Matsumoto |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-03-01
|
Series: | eNeurologicalSci |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405650221000770 |
Similar Items
-
Zonisamide for the Treatment of Parkinson Disease: A Current Update
by: Chengqian Li, et al.
Published: (2020-12-01) -
Zonisamide Ameliorates Microglial Mitochondriopathy in Parkinson’s Disease Models
by: Satoshi Tada, et al.
Published: (2022-02-01) -
Lewy body dementia: clinical manifestations, diagnosis, and treatment
by: Irina Sergeyevna Preobrazhenskaya
Published: (2012-03-01) -
Study of teratologic effects of zonisamide on neonatal rat skeletal system
by: seyyed sajjad hejazi, et al.
Published: (2017-01-01) -
Nightmare-Enacting Behavior Responding to Zonisamide in Early Parkinson’s Disease
by: Hiroshi Kataoka, et al.
Published: (2012-01-01)